InSphero is Swiss-based biotech that has been perfecting 3D cell-based drug discovery platforms and scaffold-free 3D Organ-on-a-Chip technologies for more than 10 years. InSphero deploys its patent-pending technologies for highly scalable drug discovery programs against liver diseases, T1 and T2 diabetes, and solid cancers, as well as for Safety testing with the market-leading 3D InSight™ Liver Toxicology platform. In August 2021 InSphero announced the launch of the Online R&D Solutions Store and made their proprietary, patented Akura™ 96- and 384-microwell plates available to researchers – a pivotal part of the company’s mission to enable access to industry-leading products for 3D cell culture for physiologically relevant models for disease research and drug discovery.